Dyne Therapeutics Inc (DYN) Financials
$18.42
As on 10-Sep-2026 16:00EDT
Market cap
$4,534 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
6.6
Div. Yield
0 %
Income Statement ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Operating Revenue
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cost of Revenue
|
1.07
|
2.05
|
2.24
|
2.46
|
3.35
|
1.09
|
|||||
|
Gross Profit
|
-1.07
|
-2.05
|
-2.24
|
-2.46
|
-3.35
|
-1.09
|
|||||
|
Operating Expenses
|
536.44
|
466.14
|
341.64
|
239.70
|
170.96
|
150.03
|
|||||
|
Operating Profit (EBIT)
|
-536.96
|
-468.18
|
-343.89
|
-242.16
|
-170.96
|
-150.03
|
|||||
|
Other Income
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Profit before Tax
|
-519.41
|
-446.21
|
-317.42
|
-235.94
|
-168.10
|
-149.29
|
|||||
|
Provision for Tax
|
--
|
--
|
--
|
-235.94
|
-2.86
|
-0.01
|
|||||
|
Profit after Tax (Net Income)
|
-519.41
|
-446.21
|
-317.42
|
-235.94
|
-165.24
|
-149.29
|
|||||
|
Minority Interest
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Consolidated Profit
|
--
|
--
|
--
|
--
|
-168.10
|
-149.29
|
Liabilities ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Shareholder's Funds
|
702.15
|
972.13
|
629.84
|
91.29
|
252.36
|
368.20
|
|||||
|
Minority Interest
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Non-Current Liabilities
|
213.83
|
164.20
|
19.14
|
22.70
|
25.87
|
28.74
|
|||||
|
Current Liabilities
|
78.03
|
50.63
|
42.26
|
51.10
|
28.09
|
28.72
|
|||||
|
Total Liabilities
|
1,072.04
|
1,186.96
|
691.23
|
165.08
|
306.33
|
425.66
|
Assets ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Non-Current Assets
|
56.12
|
60.37
|
31.96
|
35.71
|
40.73
|
43.27
|
|||||
|
Current Assets
|
937.89
|
1,126.59
|
659.28
|
129.38
|
265.59
|
382.39
|
|||||
|
Total Assets
|
1,072.04
|
1,186.96
|
691.23
|
165.08
|
306.33
|
425.66
|
|||||
|
Total Debt*
|
19.87
|
20.28
|
23.99
|
27.42
|
30.48
|
32.64
|
|||||
|
Net Current Assets
|
859.86
|
1,075.96
|
617.02
|
78.28
|
237.51
|
353.67
|
Cashflow ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cash From Operating Activities
|
--
|
-403.21
|
-292.37
|
-188.16
|
-153.65
|
-119.56
|
|||||
|
Cash Flow from Investing Activities
|
--
|
-28.75
|
-204.08
|
83.31
|
87.20
|
-137.89
|
|||||
|
Cash from Financing Activities
|
--
|
890.31
|
809.90
|
54.32
|
37.39
|
157.82
|
|||||
|
Net Cash Inflow / Outflow
|
--
|
--
|
--
|
--
|
--
|
--
|
Financials Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Adjusted EPS ($)
|
-3.44
|
-3.47
|
-3.11
|
-3.84
|
-3.15
|
-2.90
|
|||||
|
Cash EPS ($)
|
--
|
-3.46
|
-3.10
|
-3.82
|
-3.12
|
-2.88
|
|||||
|
Adjusted Book Value ($)
|
--
|
7.57
|
6.18
|
1.49
|
4.81
|
7.14
|
|||||
|
Dividend per Share ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cash Flow per Share ($)
|
--
|
-3.14
|
-2.87
|
-3.06
|
-2.93
|
-2.32
|
|||||
|
Free Cash Flow per Share ($)
|
--
|
-3.15
|
-2.89
|
-3.08
|
-2.99
|
-2.39
|
Profitability Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
ROCE (%)
|
--
|
-54.21
|
-82.18
|
-117.51
|
-48.34
|
-40.18
|
|||||
|
ROE (%)
|
-62.05
|
-55.71
|
-88.03
|
-137.31
|
-53.25
|
-42.02
|
|||||
|
ROA (%)
|
-56.38
|
-47.52
|
-74.14
|
-100.10
|
-45.15
|
-38.33
|
|||||
|
EBIT Margin (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Net Margin (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cash Profit Margin (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
Growth Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue Growth (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
EBIT Growth (%)
|
-20.52
|
-38.63
|
-34.54
|
-38.01
|
-14.52
|
-154.56
|
|||||
|
Net Profit Growth (%)
|
-25.80
|
-40.58
|
-34.54
|
-42.79
|
-10.68
|
-154.17
|
|||||
|
EPS Growth (%)
|
10.84
|
-0.12
|
0.19
|
-0.22
|
-0.09
|
-1.22
|
|||||
|
Book Value Growth (%)
|
-15.43
|
--
|
--
|
--
|
--
|
--
|
Valuation Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Price / Earnings
|
--
|
-5.63
|
-7.57
|
-3.46
|
-3.68
|
-4.11
|
|||||
|
Price / Book Value
|
6.64
|
2.58
|
3.81
|
8.94
|
2.41
|
1.66
|
|||||
|
Dividend Yield (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
EV/EBITDA
|
-8.87
|
-3.25
|
-5.66
|
-3.09
|
-2.26
|
-1.81
|
|||||
|
Close Price ($)
|
22.21
|
19.56
|
23.56
|
13.30
|
11.59
|
11.89
|
|||||
|
High Price ($)
|
25.00
|
26.22
|
47.45
|
15.60
|
15.63
|
32.32
|
|||||
|
Low Price ($)
|
8.06
|
6.36
|
12.33
|
6.40
|
4.30
|
11.57
|
|||||
|
Market Cap ($ Cr)
|
4,534.20
|
--
|
--
|
--
|
--
|
--
|
Solvency Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debt to Equity
|
0.28
|
0.02
|
0.04
|
0.30
|
0.12
|
0.09
|
|||||
|
Short term debt to equity ratio
|
0.01
|
0.01
|
0.01
|
0.05
|
0.02
|
0.01
|
|||||
|
Current Ratio
|
12.02
|
22.25
|
15.60
|
2.53
|
9.46
|
13.31
|
|||||
|
Quick Ratio
|
12.02
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Interest Coverage
|
-33.87
|
-71.06
|
--
|
--
|
-58.61
|
-201.20
|
Operating Efficiency Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debtors to sales (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Asset Turnover
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Receivable days
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Inventory Days
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Payable days
|
--
|
1,305.20
|
2,401.73
|
2,092.28
|
507.20
|
1,254.04
|
|||||
|
Cash Conversion Cycle
|
--
|
--
|
--
|
--
|
--
|
--
|